4.8 Article

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.
Article Cell Biology

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

Hangping Yao et al.

Summary: This study developed a therapeutic antibody cocktail against SARS-CoV-2 by exploiting antibody cooperativity, consisting of two antibodies that achieved synergistic neutralization through S1 shielding and conformational locking, blocking receptor attachment and viral membrane fusion to combat viral mutation escape. Additionally, a hypothetical third antibody partner was identified for further reinforcement as pan-SARS-CoVs therapeutics.

CELL RESEARCH (2021)

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Biochemistry & Molecular Biology

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Wanwisa Dejnirattisai et al.

Summary: Antibodies play a crucial role in immune protection against SARS-CoV-2, with some being used as therapeutics. A study identified 377 human monoclonal antibodies, focusing on 80 that bind the virus spike, and found that most highly inhibitory antibodies can block the virus-receptor interaction. Novel binding modes of potent inhibitory antibodies were discovered, showing potential for prophylactic or therapeutic use in animal models.
Article Biochemistry & Molecular Biology

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Emanuele Andreano et al.

Summary: Human monoclonal antibodies have been identified as safe, preventive, and therapeutic tools against COVID-19. Through single-cell sorting from COVID-19 survivors, a large number of spike protein-specific memory B cells have been identified, leading to the discovery of highly effective neutralizing antibodies. The most potent monoclonal antibody, engineered to reduce risk and prolong half-life, has been shown to neutralize both the original virus and emerging variants.
Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article Microbiology

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Gabriele Cerutti et al.

Summary: Structural analysis revealed that seven potent NTD-directed neutralizing antibodies target a common surface on NTD, forming a single supersite different from the recognition pattern of RBD-directed antibodies.

CELL HOST & MICROBE (2021)

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Constantinos Kurt Wibmer et al.

Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.

NATURE MEDICINE (2021)

Article Microbiology

Breadth and function of antibody response to acute SARS-CoV-2 infection in humans

Kuan-Ying A. Huang et al.

Summary: This study reports the complete mapping of antibody responses in three COVID-19 patients, finding cross-reactivity of antibodies with other betacoronaviruses and expansion of memory B cells upon SARS-CoV-2 infection. The anti-SARS-CoV-2 spike antibody clones target a diverse spectrum of epitopes, with potential of combination for combatting the outbreak.

PLOS PATHOGENS (2021)

Article Biochemistry & Molecular Biology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Matthew McCallum et al.

Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article Multidisciplinary Sciences

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Raoul De Gasparo et al.

Summary: The bispecific IgG1-like molecule CoV-X2 can simultaneously bind two independent sites on the RBD, prevent spike binding to ACE2, neutralize SARS-CoV-2 and its variants, and protect mice from disease in a mouse model of SARS-CoV-2 infection. This demonstrates the feasibility and efficacy of targeting non-overlapping RBD epitopes with IgG-like bispecific antibodies.

NATURE (2021)

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Virology

Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

Richard S. Bennett et al.

Summary: As the SARS-CoV-2 pandemic escalated, the need for effective neutralizing antibody testing became evident for the development of plasma-based therapies. By modifying and optimizing an existing fluorescence reduction neutralization assay, a high-quality neutralization assay for SARS-CoV-2 was achieved, allowing for quantitative assessment of infected cells and proficient screening of samples.

VIRUSES-BASEL (2021)

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

Article Multidisciplinary Sciences

Introductions and early spread of SARS-CoV-2 in the New York City area

Ana S. Gonzalez-Reiche et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sin Fun Sia et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski et al.

NUCLEIC ACIDS RESEARCH (2020)

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

Article Multidisciplinary Sciences

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Masaki Imai et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Structural basis of a shared antibody response to SARS-CoV-2

Meng Yuan et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

M. Alejandra Tortorici et al.

SCIENCE (2020)

Article Public, Environmental & Occupational Health

COVID-19 Outbreak at an Overnight Summer School Retreat - Wisconsin, July-August 2020

Ian W. Pray et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

Review Pharmacology & Pharmacy

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Frans V. Suurs et al.

PHARMACOLOGY & THERAPEUTICS (2019)

Article Chemistry, Physical

Repertoire Builder: high-throughput structural modeling of B and T cell receptors

Dimitri Schritt et al.

MOLECULAR SYSTEMS DESIGN & ENGINEERING (2019)

Article Medicine, General & Internal

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Biochemistry & Molecular Biology

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

Yaoxing Huang et al.

Article Medicine, General & Internal

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Midori Shima et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Multidisciplinary Sciences

Evaluation of candidate vaccine approaches for MERS-CoV

Lingshu Wang et al.

NATURE COMMUNICATIONS (2015)

Article Biochemical Research Methods

A Library of Functional Recombinant Cell-surface and Secreted P. falciparum Merozoite Proteins

Cecile Crosnier et al.

MOLECULAR & CELLULAR PROTEOMICS (2013)

Article Biochemistry & Molecular Biology

RELION: Implementation of a Bayesian approach to cryo-EM structure determination

Sjors H. W. Scheres

JOURNAL OF STRUCTURAL BIOLOGY (2012)

Article Biochemical Research Methods

Features and development of Coot

P. Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)

Article Biochemical Research Methods

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Paul D. Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Article Biochemistry & Molecular Biology

Appion: An integrated, database-driven pipeline to facilitate EM image processing

Gabriel C. Lander et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Article Biochemistry & Molecular Biology

DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy

N. R. Voss et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Article Biochemical Research Methods

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

Thomas Tiller et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2008)

Review Biochemistry & Molecular Biology

Inference of macromolecular assemblies from crystalline state

Evgeny Krissinel et al.

JOURNAL OF MOLECULAR BIOLOGY (2007)

Article Chemistry, Multidisciplinary

Phaser crystallographic software

Airlie J. McCoy et al.

JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)

Article Immunology

High affinity germinal center B cells are actively selected into the plasma cell compartment

Tri Giang Phan et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2006)

Article Biochemistry & Molecular Biology

Automated molecular microscopy: The new Leginon system

C Suloway et al.

JOURNAL OF STRUCTURAL BIOLOGY (2005)

Article Multidisciplinary Sciences

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

ZY Yang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Article Chemistry, Multidisciplinary

UCSF chimera - A visualization system for exploratory research and analysis

EF Pettersen et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)